Fiscal Year 2014 Highlights: $OXYS Revenues we
Post# of 115
Posted On: 03/31/2015 8:49:12 AM
Fiscal Year 2014 Highlights: $OXYS
Revenues were $2.4 million, up 35%, led by an 83% increase in revenues in the US
10th consecutive quarter of sales growth
Gross profit was 56% on an adjusted basis
General & administrative expense was $1.75 million
Cash was at $647,093
Capital leases decreased by $309,534
Long term debt down 42%
Working capital was a surplus of $418,734
Current ratio was 1.3
Total assets increased 7% to $2.5 million
Net loss per share for the year was $0.10
Model 615 shipments up 18%; Replacement cartridge shipments up 35%
Replacement cartridges up to 144% of Model 615 shipped
Revenues were $2.4 million, up 35%, led by an 83% increase in revenues in the US
10th consecutive quarter of sales growth
Gross profit was 56% on an adjusted basis
General & administrative expense was $1.75 million
Cash was at $647,093
Capital leases decreased by $309,534
Long term debt down 42%
Working capital was a surplus of $418,734
Current ratio was 1.3
Total assets increased 7% to $2.5 million
Net loss per share for the year was $0.10
Model 615 shipments up 18%; Replacement cartridge shipments up 35%
Replacement cartridges up to 144% of Model 615 shipped
(0)
(0)OxySure Therapeutics, Inc. (OXYS) Stock Research Links
Scroll down for more posts ▼